Radiant Biotherapeutics Appoints Deborah Geraghty, Ph.D., as President and Chief Executive Officer
Article content
Deepens leadership team and appoints Stefan Larson, Ph.D., as Chair of the Board of Directors and Ingmar Bruns, M.D., Ph.D., as a new Board Member
Article content
TORONTO — Radiant Biotherapeutics, a biotechnology company committed to advancing and delivering transformative MULTi-specific, multi-Affinity antiBODY (Multabody™) therapeutics for patients with cancer and autoimmune diseases, today announced the appointments of seasoned biotechnology executive Deborah Geraghty, Ph.D., as President and Chief Executive Officer, entrepreneur and venture investor Stefan Larson, Ph.D., as Chair of the Board of Directors, and distinguished physician-scientist Ingmar Bruns, M.D., Ph.D., as Board Member.
Stefan Larson, Ph.D., incoming Chair of Radiant Biotherapeutics, commented: 'Dr. Geraghty brings a proven track record of building and transforming innovative biotechnology companies and we are delighted to welcome her to Radiant. Her deep industry expertise and strategic vision make her the ideal CEO to lead Radiant through this next phase of growth as we advance our lead clinical candidate, a 4-1BB agonist, toward clinical trials and expand our preclinical pipeline more broadly across oncology and autoimmunity.'
Article content
Dion Madsen, outgoing Chair and continuing Board Member of Radiant Biotherapeutics, noted: 'We are thrilled to welcome Stefan and Ingmar to our board of directors as we move towards the clinic with our lead program. The addition of Dr. Larson and Dr. Bruns brings relevant expertise necessary for us to successfully deliver our next-generation biologics to patients with cancer and autoimmune diseases. We appreciate Arthur Fratamico's leadership and foundational contributions to the Company during his four-year tenure as CEO.'
Article content
These appointments follow the company's successful $35 million Series A financing and build upon the recent progress by founding Chief Scientific Officer, Jo Hulme, Ph.D. Multabody™, Radiant's proprietary, best-in-class antibody platform, leverages remarkable avidity on intended targets while exploiting specificity to address multiple epitopes and different disease-modifying proteins. Antibodies developed using the Radiant platform are designed to deliver exceptional potency against both solid tumors and blood cancers, immunological targets, and infectious disease pathogens.
Article content
Deborah Geraghty, Ph.D., President and Chief Executive Officer of Radiant Biotherapeutics, added: 'What drew me to this role are the compelling preclinical data based on the strong scientific foundation of Radiant's unique biologic platform and the team that shepherded it this far. The opportunity to drive innovation for patients and realize the value of its application for devastating cancer and autoimmune diseases is energizing and I look forward to bringing these breakthrough therapies into the clinic.'
Article content
Deborah Geraghty, Ph.D.,
Article content
is an accomplished life sciences executive with over 20 years of experience having built a strong foundation of financial, operational and strategic expertise throughout her career leading innovative biopharmaceutical companies. She most recently served as President and CEO of Anokion SA, a Phase 2 clinical-stage Swiss biotech company focused on developing a new class of immune tolerance therapies for autoimmune disease. Prior to that, she was Senior Vice President of Corporate Strategy at Dimension Therapeutics, where she led Dimension's initial public offering and subsequent acquisition by Ultragenyx in 2017. Her earlier roles include co-founder and Vice President of Project and Portfolio Development at Cydan Development and leadership positions at Aileron Therapeutics as Head of Portfolio Advancement and Infinity Pharmaceuticals as Director of New Product Marketing. Dr. Geraghty holds a B.S. in Biology from Union College, an MBA from Boston College, and a Ph.D. in Molecular Biology from the University of Vermont.
Article content
Stefan Larson, Ph.D.,
Article content
is a Venture Partner at Sectoral Asset Management and serves on several biotech boards including Prilenia Therapeutics, Apnimed, and Stratus Therapeutics. He previously was an Entrepreneur-in-Residence and later Venture Partner at Versant Ventures, where he led the establishment of their Toronto-based Discovery Engine and served as founding CEO of Northern Biologics. Dr. Larson co-founded two medical device companies, Perimeter Medical Imaging and Tornado Spectral Systems, and began his career at McKinsey & Company. He holds a B.Sc. in Biology from McGill University, an M.Sc. in Molecular and Medical Genetics from University of Toronto, and a Ph.D. in Biophysics from Stanford University.
Article content
Ingmar Bruns, M.D., Ph.D.,
Article content
is a physician-scientist with two decades of hematology and oncology expertise who currently serves as Chief Medical Officer of Zentalis. He previously served as Chief Medical Officer of Trillium Therapeutics through its acquisition by Pfizer, then held senior clinical development roles at Pfizer, including head of the hematologic malignancies franchise. Earlier positions include Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals and clinical development leadership at Bayer Pharmaceuticals. Dr. Bruns served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf and Albert Einstein College of Medicine. He has authored over 50 publications in leading journals and holds an M.D. and Ph.D. from the University of Lubeck in Germany.
Article content
About Radiant Biotherapeutics
Article content
Radiant Biotherapeutics is biotechnology company committed to advancing and delivering transformative MULTi-specific, multi-Affinity antiBODY (Multabody™) therapeutics for patients with cancer and autoimmune diseases. Radiant's proprietary platform leverages avidity and multi-specificity simultaneously, to generate highly efficacious biologics with superior potency than other antibody platforms, encompassing a new class of biologics positioned to address complex, heterogenous diseases such as cancer and autoimmune diseases. Multabody™ production and manufacturing is flexible, modular and scalable, and leverages existing antibody CMC processes. With offices in Canada and the United States, Radiant has successfully delivered on numerous strategic partnerships that validate the platform's broad scientific and clinical utility. For more information, please visit radiantbio.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
9 minutes ago
- National Post
Smarsh Named to Inc. 5000 for 18th Consecutive Year
Article content Prestigious annual ranking of the most successful private companies in America spotlights 3-year revenue growth of 114% at Smarsh Article content PORTLAND, Ore. — Smarsh, the global leader in digital communications compliance and intelligence, today announced it has been named to the Inc. 5000 list of the fastest-growing private companies in America for the 18th year in a row. This remarkable achievement underscores nearly two decades of sustained growth, innovation, and customer impact in one of the most essential and rapidly evolving sectors of enterprise technology. Smarsh is one of only two organizations in the history of the Inc. 5000 to receive this recognition 18 times. Article content Where Vision Meets Execution Article content 'Smarsh is honored to be recognized on the Inc. 5000 list for the eighteenth consecutive year,' said Kim Crawford Goodman, Chief Executive Officer of Smarsh. 'This achievement reflects how we've redefined sustainable growth and delivered lasting value for customers in financial services, government and beyond. It also speaks to our relentless pursuit of excellence across every sector we serve. By combining transformative technology with a forward-looking vision, we help our customers stay secure, competitive, and confident—especially as they navigate shifts like the rise of AI. This recognition is a testament to our people, our partners, and the culture of innovation and leadership that drives our continued success.' Article content Smarsh ranked No. 3437 on this year's list, reporting a three-year (2021–2024) revenue growth rate of 114%. The company's momentum is fueled by major innovations in compliance AI, including the industry's first solution for Microsoft Copilot Capture and an Intelligent Agent that applies cutting-edge AI to find risk in communications data efficiently. Smarsh supports a wide range of organizations, from emerging advisory firms to 18 of the top 20 global banks, helping them meet the requirements of the SEC, FINRA, and other regulators around the world. Article content Execution That Delivers Results Article content This recognition comes amid a year of strong momentum for Smarsh, marked by multiple accolades for its innovation, vision and culture. Recent honors include the 2025 Silver Globee Award for 'Best Use of AI in Finance,' a spot on the 2025 AIFINTECH100 list of the world's most innovative AI companies in financial services, and recognition as a 2025 USA TODAY Top Workplace. These accomplishments demonstrate leadership in delivering secure, scalable and future-ready solutions for the world's most regulated industries. Article content 'Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision,' says Mike Hofman, editor-in-chief of Inc. 'These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.' Article content About Smarsh Article content Smarsh enables companies to transform oversight into foresight by surfacing business-critical signals in their digital communications. Serving the top banks, insurers, investment firms, and government agencies worldwide, Smarsh delivers cloud-native solutions that help organizations stay compliant, mitigate risk, and unlock the value of their communications data. Learn more at or follow us on LinkedIn. Article content About Inc. Article content Article content Article content Article content
National Post
9 minutes ago
- National Post
Annual Research Service: 970+ Industries Profiled Across the U.S. and Canada
Article content Article content DUBLIN — The 'Vertical IQ Annual Research Subscription: 970+ Industries Profiled Across the U.S. and Canada' report has been added to offering. Article content As a leader in industry-specific research, the publisher presents a focused, actionable, and relevant platform of industry reports, local economic reports, curated news, and financial comparisons designed to educate, support, and enable sales and customer service professionals to quickly become 'industry experts' and to drive better conversations and outcomes with their clientele. Article content What's included in the Vertical IQ platform? Article content Platform Benefits Article content Become Your Clients' Most Valuable Resource: Your clients need strategic insight about their industries – and the industries they sell to. Understand their business environment so that you become an indispensable member of their team. Timely and Time-Saving Content: We've done the research for you. Provide timely, strategic insight specific to your client's industry – without spending a ton of research time. Shareable Content: This is content clients want, so delight them by sharing it! Deliver financial comparisons and detailed local economic data. Support Your Recommendations: Validate industry trends for valuations, litigation support, audits, and more. Article content How Will The Platform Help Me? Article content Prep for client meetings by understanding your client's industry Assess competitive best practices to help your clients business Provide clients and prospects with intelligence on the industries they sell to Validate industry trends and events for sales presentations, strategic analysis, valuation, litigation support, audit, consulting, and many other services Help clients make strategic planning decisions, such as which new markets to enter Build industry-specific campaigns, collateral, and content Improve your marketing with industry-specific insight and content Article content See for yourself why more than 60,000 users trust the publisher for their industry research and call preparation needs. Their easy-to-digest industry insights save call preparation time and help differentiate you from the competition. Build valuable, lasting relationships by having smarter conversations. Article content For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Article content Article content Article content Article content Article content Contacts Article content Article content
Globe and Mail
9 minutes ago
- Globe and Mail
Stocks in play: Oncolytics Biotech Inc
Announced the voting results from its Annual General Meeting of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. Oncolytics Biotech Inc shares are trading unchanged at $0.86.
